First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration

Talks, James; Lotery, Andrew; Ghanchi, Faruque; Sivaprasad, Sobha; Johnston, Robert L.; Patel, Nirmal; McKibbin, Martin; Bailey, Clare; Mahmood, Sajjad; Lobo, Aires; Paul, Bobby; Kashif, Qureshi; Santiago, Celine; Walters, Gavin; Tahir, Mohamed Ibrahim Mohamed; Mushtaq, Bushra

doi:10.1016/j.ophtha.2015.09.039

Cited by 91 publications

(87 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The superiority of the aflibercept response in our study is likely due to the different baseline visual acuities as well as the different subjects limited to PCV. A greater BCVA improvement in lower baseline visual acuity has previously been reported 20 21. The baseline visual acuity was 53.6 ETDRS letters in the VIEW study and 45 approximate ETDRS letters in our study.…”

Section: Discussionsupporting

confidence: 60%

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Jeong

Sagong

2016

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 60%

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Jeong

Sagong

2016

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…By the end of year 1, a median of eight injections had been administered over a median of eight visits per patient, resulting in a mean gain of 5.1 ETDRS letters [81]. …”

Section: Results: the Principles Of An Ideal Treatment Regimenmentioning

confidence: 99%

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases

Lanzetta

Loewenstein

2017

Graefes Arch Clin Exp Ophthalmol

137

146

View full text Add to dashboard Cite

BackgroundIntravitreal anti–vascular endothelial growth factor (VEGF) therapy is now considered the gold standard for the treatment of various retinal disorders. As therapy has evolved, so too have the treatment regimens employed by physicians in clinical practice; however, visual outcomes observed in the real world have typically not reflected those reported in clinical trials. Possible reasons for this include a lack of consensus on treatment regimens and a lack of clarity about what the aims of treatment should be.MethodsThe Vision Academy Steering Committee met to discuss the principles of an ideal treatment regimen, using evidence from the literature to substantiate each point. Literature searches were performed using the MEDLINE/PubMed database (cut-off date: March 2016) and restricted to English-language publications. Studies with fewer than ten patients were excluded from this review.ResultsThe Steering Committee identified the following four key principles for the ideal treatment regimen for anti-VEGF management of retinal diseases:Maximize and maintain visual acuity (VA) benefits for all patientsDecide when to treat next, rather than whether to treat nowTitrate the treatment intervals to match patients’ needsTreat at each monitoring visit. ConclusionsIt is proposed that the adoption of a proactive and more personalized approach in the clinic such as a treat-and-extend regimen will lead to benefits for both the patient and the physician, through a reduction in the associated treatment burden and better utilization of clinic resources. Implementation of the four principles should also lead to better VA outcomes for each patient, with a minimized risk of vision loss.

show abstract

“…Our study, which was carried out in routine daily practice, confirms optimal vision gains and anatomic disease control previously reported in two large clinical trials involving more than 2,400 patients with nvAMD [25] as well as in the 96-week extension of these trials [26]. Also, a number of observational studies have shown the beneficial effect of aflibercept therapy for nvAMD in both resistant to other VEGF inhibitors (bevacizumab and ranibizumab) [27,28,29,31,32] and as first line in clinical practice [33,34]. …”

Section: Discussionmentioning

confidence: 98%

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

et al. 2016

View full text Add to dashboard Cite

Purpose: To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. Methods: Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months. Results: At 3 and 13 months, the mean best-corrected visual acuity improved significantly as compared with baseline (logMAR 0.53 ± 0.30 and 0.55 ± 0.32 vs. 0.30 ± 0.24, respectively, p < 0.001). At 3 and 13 months, 46.8% of patients (15/32) gained ≥15 ETDRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 ± 35 µm) and at 13 months (249 ± 38 µm) as compared with pretreatment values (383 ± 76 µm) (p < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 out of 9 eyes (88.9%) with PED at baseline. Intravitreal injections were well tolerated and no adverse events were recorded. Conclusion: Aflibercept was effective and safe for treating nvAMD in naïve patients in routine daily practice.

show abstract

First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration

Cited by 91 publications

References 12 publications

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

Contact Info

Product

Resources

About